Replies to post #156284 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

"tax rebate" is a misleading description. it is a

43.5% “cash back” benefit

against the R&D expenses the company's Australian entity incurs.

R&D Tax Incentive

Maybe we can move on to something else once you have read this.

[Steady_T]

We have been through this issue many times. Please refer to the 10K filings where REVENUES are recognized on the balance sheet for the Aussie trial.

The offset to income is a bogus argument.

[F1ash]

Feel free to post actual links to actual money they have received that would obviate the need for substantial more dilution and funding. Tax breaks are
Not that.

Well yes and no.

The necessity of dilution is dependent on how much it costs to run the trials. If it costs less to run the Alzheimer’s trial, then the money Anavex has on the books currently will last longer.

If a penny saved is a penny earned, then a rebate is really similar to a grant imho.

I’ll let you check into the following further to tell me if I’m incorrect:

I believe the “tax” portion is a bit misleading. I believe many think it means that the “taxes” are just reduced, but that’s not how I read the following. In some ways very similar to a grant or partnership imho.

“Planning to run a clinical trial in Australia?
43.5% “cash back” benefit now available for eligible foreign companies undertaking R&D in Australia. Are you eligible for up to 43.5% refund on your next Clinical Trial?”

https://datapharmaustralia.com/r-d-tax-incentive/

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=141067684

Check the video.

The benefits are actually larger for companies with -0- revenue than companies that are registering a profit as an illustration of why “tax” rebate is a misleading term imho.